AI medical solutions company Aidot (CEO Jaehoon Jeong) received an "Excellent" rating in all three national and local government support projects for its three AI solutions (Cerviray AI, ECHO dot AI, and URO dot AI). Building on the field evidence secured through empirical and clinical trials, Aidot is now actively expanding its market and launching follow-up commercialization.

The "Excellent" rating signifies that the company has successfully translated government projects into actual business operations, conducted 100% qualitative and quantitative evaluations, and pursued export capabilities and commercialization, all funded by taxpayer dollars.

Under the "2025 Gangwon AI Healthcare Enterprise Development Support Project," Aidot conducted a local validation project for Cerviray AI (an AI system for assisting in cervical cancer diagnosis) and an overseas certification project for ECHO dot AI (an AI system for assisting in assisting in otitis media diagnosis). Under the "2025 Domestic Medical Device User (Medical Institution) Evaluation Support Project," Aidot conducted a multi-institutional evaluation of URO dot AI (a software system for assisting in assisting in urinary stones diagnosis).

The evaluation stated that the project results "have high potential for future use in the AI ​​healthcare field."

The quantitative results of the overseas certification and on-site validation projects met the planned level, and additional achievements, such as technological advancements, were also noted as positive.

Furthermore, Aidot received feedback that the support project contributed to technological advancement and increased overseas sales. The overall evaluation recognized Aidot as an "excellent performer who faithfully and effectively carried out the project."

By product, Cerviray AI conducted a local validation project at an Indonesian hospital to assess its applicability to the medical environment and operational processes.

ECHO dot AI has laid the groundwork for overseas expansion by preparing for FDA 510(k) and CE MDR certification.

URO dot AI's applicability in clinical settings was assessed through a multi-institutional evaluation at domestic medical institutions. The application of AI-assisted interpretation reduced the average interpretation time from 70 seconds to 25 seconds (a 64.49% reduction).

The company announced plans to accelerate commercialization by simultaneously expanding domestic clinical applications and preparing for overseas expansion, based on the evidence and field references obtained through the validation and clinical evaluations.

Key features of Cerviray AI include: 1) on-device AI interpretation (no internet required, instant results provided); 2) MFDS Class 3 approved AI medical device; 3) lesion classification results (CIN1 / CIN2/3 / CIN3+); and 4) the display of detailed lesion detection boxes.